Tex. Health & Safety Code § 1003.051 · Subchapter B. PROVISION OF INVESTIGATIONAL STEM CELL TREATMENTS TO PATIENTS WITH CERTAIN SEVERE CHRONIC DISEASES OR TERMINAL ILLNESSES
DEFINITIONS.
Text — Current through the 89th 2nd Called Legislative Session, 2025
In this subchapter:
(1) "Investigational stem cell treatment" means an adult stem cell treatment that:
(A) is under investigation in a clinical trial and being administered to human participants in that trial; and
(B) has not yet been approved for general use by the United States Food and Drug Administration.
(2) "Severe chronic disease" means a condition, injury, or illness that:
(A) may be treated;
(B) is never cured or eliminated; and
(C) entails significant functional impairment or severe pain.
(3) "Terminal illness" means an advanced stage of a disease with an unfavorable prognosis that, without life-sustaining procedures, will soon result in death or a state of permanent unconsciousness from which recovery is unlikely.
Notes and commentary — not statutory text
History
Added by Acts 2017, 85th Leg., R.S., Ch. 697 (H.B. 810), Sec. 3, eff. September 1, 2017.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/HS/htm/HS.1003.htm
- Text hash
- sha256 f9d739e2ccb4e371cfa76599922fda53b67a4be72f21e1fc75d030d85d51ee17
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.